The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13,542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.
Wang
W
W
Department of Evidence-Based Medicine, Cardiovascular Institute and Fuwai Hospital, Beijing, PR China.
Ma
L
L
Zhang
Y
Y
Deng
Q
Q
Liu
M
M
Liu
L
L
D000368:Aged; D000584:Amiloride / Q000627:therapeutic use; D017311:Amlodipine / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D016009:Chi-Square Distribution; D002681:China; D004232:Diuretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D000077333:Telmisartan; D013997:Time Factors; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D002121:Calcium Channel Blockers; D004232:Diuretics; D006852:Hydrochlorothiazide; D017311:Amlodipine; D000584:Amiloride; D000077333:Telmisartan
BMJ. 2004 Mar 13;328(7440):634-40
15016698
Lancet. 2005 Jan 15-21;365(9455):217-23
15652604
J Hypertens. 2001 Jun;19(6):1139-47
11403364
BMJ. 2009 May 19;338:b1665
19454737
Drugs. 2004;64 Suppl 2:43-60
15765890
Blood Press. 2007;16(1):13-9
17453747
Eur Heart J. 2007 Jun;28(12):1462-536
17562668
Am J Hypertens. 2004 Sep;17(9):793-801
15363822
Postgrad Med. 2009 Mar;121(2):5-14
19332958
Eur Heart J. 2003 Sep;24(17):1601-10
12964575
J Hypertens. 2009 May;27(5):947-54
19318984
Hellenic J Cardiol. 2006 Jan-Feb;47(1):21-8
16532712
Am Heart J. 2004 Jul;148(1):52-61
15215792
J Hypertens. 2007 Jun;25(6):1105-87
17563527
Vasc Health Risk Manag. 2009;5(1):213-24
19436667
JAMA. 2002 Dec 18;288(23):2981-97
12479763
Lancet. 2001 Oct 20;358(9290):1305-15
11684211
Hypertension. 2003 Dec;42(6):1206-52
14656957
Hypertens Res. 2009 Feb;32(2):163-7
19262477
J Hypertens. 2005 Dec;23(12):2157-72
16269957
J Hypertens. 1996 Oct;14(10):1237-45
8906524
N Engl J Med. 2001 Jan 4;344(1):3-10
11136953
Arch Intern Med. 2000 Jan 24;160(2):211-20
10647760
Eur Heart J. 2006 Dec;27(24):2982-8
17145722
JAMA. 2002 Dec 18;288(23):2998-3007
12479764
J Hypertens. 2003 Apr;21(4):707-16
12658016
Clin Exp Hypertens. 2005 May;27(4):331-41
15921070